Navigation Links
Hit multiple targets for maximum benefit in HER2-positive breast cancer, studies suggest
Date:3/8/2011

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators.

The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes of targeted therapies (HER2- and PI3 kinase-targeted therapies). Therefore targeting HER3 together with these agents should improve their clinical utility.

Around 25 percent of breast cancers have increased expression of the HER2 receptor, which is associated with more aggressive tumors and a poorer prognosis. HER2-targeted therapies like trastuzumab (Herceptin) and lapatinib (Tykerb) are effective in many women with HER2-positive breast tumors.

"But even in patients who respond to HER2-targeted therapies, the clinical response tends to be short-lived and tumors become resistant," said Carlos Arteaga, M.D., professor of Medicine and Cancer Biology, and director of the VICC Breast Cancer Research Program.

HER2 is a member of the EGF receptor family involved in signaling pathways that promote cell growth. HER2 must interact and form complexes with other members of the EGF receptor family, and its main partner in activating pathways that promote tumor growth is HER3. This complex of HER2/HER3 is a potent activator of the PI3K/Akt pathway, the key survival pathway in HER2-positive cancers.

"Based on this evidence, we hypothesized that, for these therapies to have maximum effect, HER3 and its output to the PI3K/Akt pathway must be completely shut down," Arteaga said.

A postdoctoral fellow in Arteaga's laboratory, Joan Garrett, Ph.D., led experiments to examine the effect of the HER2 tyrosine kinase inhibitor, lapatinib, on HER3 expression and activity.

She found that inhibiting HER2 with lapatinib led to an increase in HER3
'/>"/>

Contact: Melissa Marino
melissa.marino@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Multiple sclerosis blocked in mouse model
2. Psoriasis medication rises hope in the fight against multiple sclerosis
3. How sunlight may reduce the severity of multiple sclerosis
4. Multiple childbirth linked to increased risk of rare, aggressive triple-negative breast cancer
5. Wayne State University researchers publish results settling multiple sclerosis debate
6. VCU Massey first to combine targeted agents to kill multiple myeloma cells
7. Most ADHD Kids Have Multiple Conditions, Study Says
8. More than allergies: Histamine may be a possible drug target for multiple sclerosis
9. Tiny RNA shown to cause multiple types of leukemia
10. Laboratory studies show promise for new multiple sclerosis treatment
11. Common for patients to undergo multiple cardiac imaging tests, with high cumulative radiation dose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... 2015 Pioneer Millworks reclaimed USA wood ... & Construction Materials Show, an annual, premier sustainable building ... suppliers and top manufacturers of the latest building products, ... sourced and manufactured by Pioneer Millworks from their ... Japan at restaurants, hotels, retailers, and corporate offices. ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Kaylie Corrigan, ... alcohol treatment center , and current student obtaining her ... has implemented a weekly forum in psychoeducation on substance ... in Flagstaff, AZ as part of her studies. , ... need for support and counseling at the high school ...
(Date:2/28/2015)... February 28, 2015 Developers of FCPX ... a new overlay plugin for Final Cut Pro X entitled ... “FCPX Overlay Chromatic gives users total control over 6k lens ... CEO of Pixel Film Studios. “FCPX Overlay Chromatic was professionally ... to use interface.” , FCPX Overlay Chromatic Grunge 6K is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The World ... and learning materials to potential EMTs and firefighters, recently ... Bitcoins as a way to raise charitable donations for ... in Medellin, Columbia, will be held on March 29, ... run will begin at 3:30 p.m. , To ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 OnChip ... (IPD), has introduced miniature, wire bondable, silicon ESD (Electrostatic ... LED markets. The ESD88NP and ... away from sensitive LED and IC products. These ... Varistors (MLV). All devices meet the requirements of ...
Breaking Medicine News(10 mins):Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... York have achieved a breakthrough of sorts in cancer ... to a key position on cancer cells and gives ... of advanced colorectal cancer patients. ,IMC-C225, the new ... to interfere with the epidermal growth factor receptor, a ...
... is one of the worst types of chronic pain. ... painful condition. But now there’s good news for the ... the most popular forms of alternative medicine, is supposed ... ,A team led by Dr. Jeanette Ezzo, Washington, ...
... of the journal Epidemiology, high levels of DDT found in ... function. The human body metabolises DDT to DDE. An international ... 16 to 28 who had not been exposed to DDT ... levels correlated to low levels of testosterone, low semen volume ...
... Millions of postmenopausal women suffer from sexual dysfunctions- ... physiological and psychological problems. ,However if the ... these problems can be treated properly. Almost all ... develop changes in genital organs-particularly a condition known ...
... in four countries have unanimously opined that the deadly ... from an oral polio vaccine used in Africa in ... no scientific evidence to back them up. ,The ... Germany, should help free the polio vaccine manufactured by ...
... Thursday that plans are afoot to consider listing on US ... bourses after 2002," Pratap C Reddy, chairman of the Apollo ... business plan for the post-2002 period. ,Though further details ... plans to raise the number of beds to 8000 from ...
Cached Medicine News:
(Date:2/27/2015)... Feb. 27, 2015 The role of the ... but one thing hasn,t changed: face-to-face meetings are seen ... with Key Opinion Leaders. Yet at the ... valuable type of interaction, field medical teams within the ... interactions. This is just one of the challenges addressed ...
(Date:2/27/2015)... YORK , Feb. 27, 2015  Pomerantz LLP ... Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Vitae and certain of its officers and/or directors have ... Act of 1934.  On February 27, ...
(Date:2/27/2015)...  Acsis Inc., the market leader for supply chain ... John DiPalo , Acsis, Chief Strategy Officer, has ... Executive 2015 Provider Pro to Know. The award ... help prepare their companies, and customers, supply chains for ... list of Provider Pros to Know is featured in ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... immunogenicity results for seasonal vaccine program follows positive results from ... plans to initiate a study of the seasonal vaccine in ... ROCKVILLE, Md., Dec. 11 Novavax, Inc. (Nasdaq: ... Phase IIa human clinical trial of its seasonal influenza VLP ...
... 11 ,Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ... ) and Alkermes, Inc. (Nasdaq: ALKS ... Administration (FDA) recently indicated that the ongoing extension ... the basis for demonstrating,comparability between intermediate-scale clinical trial ...
Cached Medicine Technology:Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 2Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 3Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 4Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 5Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 6Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 2Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 3Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 4Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 5Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 6Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback 7
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... CVMstat® provides leading ... of topics involving all ... including sections on diagnosis ... arterial and venous disease. ...
... to the management of common ... a response from leading experts ... more common, and often poorly ... It is a "how-to" guide ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: